コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 gastrointestinal symptoms as the most common systemic side effect.
2 for kidney disease treatment because of its systemic side effects.
3 ortunity for localized treatments that avoid systemic side effects.
4 sue, since this can be devoid of central and systemic side effects.
5 little extrahepatic exposure, thus limiting systemic side effects.
6 cells results in targeted delivery and fewer systemic side effects.
7 riad of localized diseases while eliminating systemic side effects.
8 ng to plaque development without significant systemic side effects.
9 g daily, 30 days) did not cause any local or systemic side effects.
10 xacerbate antimicrobial resistance and cause systemic side effects.
11 inst epilepsy and neuropathic pain but cause systemic side effects.
12 ing a noninvasive local therapy with limited systemic side effects.
13 protective benefits without the significant systemic side effects.
14 etes and military personnel-while minimizing systemic side effects.
15 tumour treatment and reduces recurrence and systemic side effects.
16 antitumor immune responses while minimizing systemic side effects.
17 tor E2-related factor 2 (NRF2) is limited by systemic side effects.
18 on is using high drug doses that can lead to systemic side effects.
19 the blood-brain-barrier (BBB) and eliminates systemic side effects.
20 effects, they complicate treatment and risk systemic side effects.
21 were well tolerated with no severe local or systemic side effects.
22 rugs and they are associated with ocular and systemic side effects.
23 ed clinical trials because of their unwanted systemic side effects.
24 metastatic liver cancer, without increasing systemic side effects.
25 improve cardiac function but are limited by systemic side effects.
26 g expansion of aneurysms in patients without systemic side effects.
27 patient tolerance and no noticeable local or systemic side effects.
28 to control/eradicate HIV as well as mitigate systemic side effects.
29 se in situ efficacy of the drug and minimize systemic side effects.
30 unds drives myocardial contractility without systemic side effects.
31 lity of drug and the potential for local and systemic side effects.
32 sia restored rcSO2 to control levels with no systemic side effects.
33 igh efficacy, low operative morbidity and no systemic side effects.
34 fic delivery would inevitably cause unwanted systemic side effects.
35 cations, including multiorgan toxicities and systemic side effects.
36 than SLIT alone but was accompanied by more systemic side effects.
37 es and may allow reduced systemic dosage and systemic side effects.
38 compound alone was directly associated with systemic side effects.
39 ral ischemia-related injury while minimizing systemic side effects.
40 ote long-term engraftment without associated systemic side effects.
41 cells, but can be associated with local and systemic side effects.
42 ied counterparts, due to the reduced rate of systemic side effects.
43 also be expected to reduce the potential for systemic side effects.
44 in a dose-related, reversible manner without systemic side effects.
45 fects to the lung vasculature, thus avoiding systemic side effects.
46 ment of myopia, but has undesired ocular and systemic side effects.
47 zer; however, its clinical use is limited by systemic side effects.
48 and colon carcinoma without any significant systemic side effects.
49 may be of benefit although at the expense of systemic side effects.
50 necessary, without any significant local or systemic side effects.
51 strategies without significant drug-specific systemic side effects.
52 immunosuppressive options are limited due to systemic side effects.
53 ired anti-inflammatory activity and unwanted systemic side effects.
54 owed better efficacy than PDT alone, without systemic side effects.
55 TG was similar, limiting the opportunity for systemic side effects.
56 e via site-specific strategies that minimize systemic side effects.
57 e often challenging, costly, and may lead to systemic side effects.
58 -specific immune mechanisms while minimizing systemic side effects.
59 oth mTORC1 and mTORC2 and is associated with systemic side-effects.
60 linical benefits, these drugs are limited by systemic side-effects.
62 orbed into the bloodstream, which results in systemic side effects and a brief residence time in the
64 press the immune system in order to minimize systemic side effects and deliver sufficient nanoparticl
65 nts directly to inflammation sites, reducing systemic side effects and improving patient outcomes.
66 ential to significantly decrease undesirable systemic side effects and reduce required therapeutic do
67 is associated with local and, in some cases, systemic side effects and suffers from low patient compl
69 ness and itching) but a similar incidence of systemic side effects and was preferred by study partici
70 -care drug ciprofloxacin suffers from severe systemic side effects and was therefore chosen for this
71 h nystatin, a renal-protective compound with systemic side effects, and efficiently targeted injured
72 the dependence on operator technique, reduce systemic side effects, and facilitate reproducibility ac
74 he transplanted allograft, which would limit systemic side effects, and prolong allograft survival.
76 eroid dose that causes the same magnitude of systemic side effects as oral prednisone at a 5-mg daily
77 advanced the understanding of mechanism for systemic side effects associated with intravitreal anti-
79 in immune mediated diseases while minimizing systemic side effects associated with standard GC treatm
80 he immune system, coupled with the potential systemic side effects associated with traditional system
81 ectly to the site of inflammation and avoids systemic side effects but often fails to modulate system
82 tments for many CNS diseases, while reducing systemic side effects by providing sustained, well-dispe
83 e, it seems reasonable to classify and grade systemic side effects by using the previously published
84 that some patients could have misattributed systemic side effects caused by the zoster vaccine to th
85 to 7 years with no evident increased risk of systemic side effects compared with regional corticoster
86 vascular endothelial cells, cytotoxicity and systemic side effects dampen enthusiasm for their use in
87 cally, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology.
88 however, can be associated with significant systemic side effects due to the drugs' lack of tissue s
89 ept in strict isolation to monitor local and systemic side-effects, environmental spread, and anti-E6
90 arding IVB treatment of ROP is the potential systemic side effects, especially the risk of causing se
91 atient tolerance is often poor due to common systemic side effects following oral administration.
94 of action than the B serotype and has fewer systemic side effects; hence, it is more likely to gain
95 trast, the recombinant zoster vaccine causes systemic side effects in a large proportion of patients.
98 rate slower tumor growth that did not induce systemic side effects, including weight loss in an exper
99 se of drug in the tumor while minimizing its systemic side effects is one of the important features o
106 en considered to have therapeutic potential, systemic side effects of IGF-1 are significant, and loca
111 function (p=0.0053), fatigue (p<0.0001), and systemic side-effects (p<0.0001), but not role functioni
112 function (p<0.0001), fatigue (p=0.0002), and systemic side-effects (p=0.0001), but not sexual functio
113 is is impaired by poor drug bioavailability, systemic side effects, patient non-compliance, and patho
114 ctogenicity, the occurrence of adverse local/systemic side effects, plays a crucial role in vaccine u
115 with low objective response rates and severe systemic side effects still remain and limit its clinica
117 uximab, lapatinib, and panitumumab have less systemic side-effects than traditional cytotoxic chemoth
118 hat can result in antidrug antibodies and/or systemic side effects that limit long-term benefits.
119 are an APOE4-specific AD therapeutic and the systemic side effects that limit translational applicati
120 opical formulations, which mitigated several systemic side effects; the expansion of drug classes tar
121 focal light irradiation, thereby minimizing systemic side effects to the normal healthy tissues.
122 ploration of the dual-soft concept to reduce systemic side effects via rapid elimination: introducing
123 compromising the immune system or eliciting systemic side effects, we investigated the use of T-bet-
129 lfoxide (DMSO), which can cause a variety of systemic side effects when the graft is thawed and infus
131 icant increase in the incidence of local and systemic side effects, which was felt to outweigh the sm
132 caused any detectable epithelial toxicity or systemic side effects with very low drug levels measured